• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一期非小细胞肺癌中 mTOR 通路的免疫组化特征。

Immunohistochemical characterization of the mTOR pathway in stage-I non-small-cell lung carcinoma.

机构信息

Department of Pathology, Seoul National University Bundang Hospital, 173-82 Gumiro, Bundang-gu, Seongnam 463-707, Gyeonggi-do, Republic of Korea.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, 138-736 Seoul, Republic of Korea.

出版信息

Lung Cancer. 2015 Jul;89(1):13-8. doi: 10.1016/j.lungcan.2015.04.003. Epub 2015 Apr 14.

DOI:10.1016/j.lungcan.2015.04.003
PMID:25936472
Abstract

BACKGROUND

Dysregulation of mammalian target of rapamycin (mTOR) pathway has been linked with malignant tumorigenesis. This study explored the expression profiles of proteins involved in the mTOR pathway and their relationships with clinicopathologic characteristics in stage-I non-small-cell lung carcinoma (NSCLC).

METHODS

The protein expression profiles of PTEN, p-Akt, p-mTOR, p-S6, and eIF4E were examined using immunohistochemical staining and tissue microarray method in 408 patients with stage-I NSCLC (250 adenocarcinomas [ADC] and 158 squamous cell carcinomas).

RESULTS

Retained PTEN expression (P<0.001), p-mTOR expression (P<0.001), and p-S6 expression (P=0.007) were associated with ADC histology. Expression of PTEN (P=0.001), p-Akt (P=0.005), p-mTOR (P=0.007), p-S6 (P<0.001) were correlated with lower pathologic T stage. PTEN loss was correlated with male gender and smoking history and p-mTOR expression was inversely correlated with these factors (P<0.001). Subgroup analysis of ADCs indicated that male gender, high pT stage, lymphovascular invasion, and PTEN loss were poor prognostic factors. Multivariate analysis revealed that the PTEN(-)/p-Akt(+)/p-mTOR(+) combination more effectively determined the prognosis of ADC (hazard ratio=2.2, P=0.004) than PTEN alone.

CONCLUSIONS

Activation of the mTOR pathway in early-stage ADCs suggests a significant role for the mTOR axis in early carcinogenesis. The combination of PTEN(-)/p-Akt(+)/p-mTOR(+) expression was correlated with poor overall survival in patients with stage-I lung ADC.

摘要

背景

哺乳动物雷帕霉素靶蛋白(mTOR)通路的失调与恶性肿瘤发生有关。本研究探讨了 mTOR 通路相关蛋白的表达谱及其与 I 期非小细胞肺癌(NSCLC)临床病理特征的关系。

方法

采用免疫组织化学染色和组织微阵列方法检测 408 例 I 期 NSCLC 患者(250 例腺癌[ADC]和 158 例鳞状细胞癌)中 PTEN、p-Akt、p-mTOR、p-S6 和 eIF4E 的蛋白表达谱。

结果

保留的 PTEN 表达(P<0.001)、p-mTOR 表达(P<0.001)和 p-S6 表达(P=0.007)与 ADC 组织学相关。PTEN(P=0.001)、p-Akt(P=0.005)、p-mTOR(P=0.007)和 p-S6(P<0.001)的表达与较低的病理 T 分期相关。PTEN 缺失与男性和吸烟史相关,p-mTOR 表达与这些因素呈负相关(P<0.001)。ADC 的亚组分析表明,男性、高 pT 分期、血管淋巴管侵犯和 PTEN 缺失是不良预后因素。多因素分析显示,PTEN(-)/p-Akt(+)/p-mTOR(+)联合较单独 PTEN 更能有效判断 ADC 的预后(危险比=2.2,P=0.004)。

结论

早期 ADC 中 mTOR 通路的激活表明 mTOR 轴在早期癌变中起重要作用。PTEN(-)/p-Akt(+)/p-mTOR(+)表达的组合与 I 期肺 ADC 患者的总生存期不良相关。

相似文献

1
Immunohistochemical characterization of the mTOR pathway in stage-I non-small-cell lung carcinoma.一期非小细胞肺癌中 mTOR 通路的免疫组化特征。
Lung Cancer. 2015 Jul;89(1):13-8. doi: 10.1016/j.lungcan.2015.04.003. Epub 2015 Apr 14.
2
Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.非小细胞肺癌中磷酸化Akt的过表达和PTEN表达的缺失预示着不良预后。
Lung Cancer. 2006 Feb;51(2):181-91. doi: 10.1016/j.lungcan.2005.10.003.
3
A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.肺癌中 PI3K/AKT/mTOR 通路的详细免疫组化分析:与 PIK3CA、AKT1、K-RAS 或 PTEN 基因突变状态及临床病理特征的相关性。
Oncol Rep. 2013 Aug;30(2):623-36. doi: 10.3892/or.2013.2512. Epub 2013 May 31.
4
Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.纤连蛋白通过激活Akt/雷帕霉素哺乳动物靶蛋白/S6激酶以及使LKB1/AMP激活的蛋白激酶信号通路失活来刺激非小细胞肺癌细胞生长。
Cancer Res. 2006 Jan 1;66(1):315-23. doi: 10.1158/0008-5472.CAN-05-2367.
5
Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma.哺乳动物雷帕霉素靶蛋白通路标志物在肺腺癌和肺鳞癌中的表达。
Pathobiology. 2012;79(2):84-93. doi: 10.1159/000334340. Epub 2012 Jan 27.
6
Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer.磷酸化 eIF4E 的过表达与非小细胞肺癌中 AKT 通路的存活有关。
Clin Cancer Res. 2010 Jan 1;16(1):240-8. doi: 10.1158/1078-0432.CCR-09-0986. Epub 2009 Dec 15.
7
Overexpression of p-Akt, p-mTOR and p-eIF4E proteins associates with metastasis and unfavorable prognosis in non-small cell lung cancer.p-Akt、p-mTOR 和 p-eIF4E 蛋白的过表达与非小细胞肺癌的转移和不良预后相关。
PLoS One. 2020 Feb 5;15(2):e0227768. doi: 10.1371/journal.pone.0227768. eCollection 2020.
8
Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.表皮生长因子受体/ Akt 下游激酶驱动通路在人肺癌中的作用模式。
Hum Pathol. 2011 Feb;42(2):214-26. doi: 10.1016/j.humpath.2010.05.025. Epub 2010 Oct 30.
9
Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.mTOR通路在肾细胞癌中的预后相关性:对分子靶向治疗患者选择的意义
Cancer. 2007 Jun 1;109(11):2257-67. doi: 10.1002/cncr.22677.
10
Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.新辅助化疗后非小细胞肺癌患者的长期生存与特定分子改变相关。
Exp Mol Pathol. 2015 Feb;98(1):27-32. doi: 10.1016/j.yexmp.2014.11.010. Epub 2014 Nov 20.

引用本文的文献

1
The clinicopathological and prognostic significance of mTOR and p-mTOR expression in patients with non-small cell lung cancer: A meta-analysis.mTOR 及其磷酸化形式 p-mTOR 在非小细胞肺癌患者中的表达与临床病理及预后的关系:一项荟萃分析。
Medicine (Baltimore). 2022 Dec 23;101(51):e32340. doi: 10.1097/MD.0000000000032340.
2
Impact of L-type amino acid transporter 3 on the prognosis of hepatocellular carcinoma.L型氨基酸转运体3对肝细胞癌预后的影响
Oncol Lett. 2022 Sep 30;24(5):418. doi: 10.3892/ol.2022.13538. eCollection 2022 Nov.
3
PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC).
非小细胞肺癌(NSCLC)患者在奥希替尼治疗期间循环肿瘤细胞(CTC)中的程序性死亡受体配体1/磷酸化核糖体蛋白S6
Biomedicines. 2022 Aug 5;10(8):1893. doi: 10.3390/biomedicines10081893.
4
Expression and significance of mammalian target of rapamycin in cutaneous squamous cell carcinoma and precancerous lesions.哺乳动物雷帕霉素靶蛋白在皮肤鳞状细胞癌及癌前病变中的表达及意义。
Bioengineered. 2021 Dec;12(2):9930-9938. doi: 10.1080/21655979.2021.1984719.
5
Low PTEN expression and overexpression of phosphorylated Akt and Akt are associated with poor overall survival in upper tract urothelial carcinoma.低PTEN表达以及磷酸化Akt和Akt的过表达与上尿路尿路上皮癌的总体生存率低相关。
Oncol Lett. 2020 Dec;20(6):347. doi: 10.3892/ol.2020.12210. Epub 2020 Oct 9.
6
Overexpression of p-Akt, p-mTOR and p-eIF4E proteins associates with metastasis and unfavorable prognosis in non-small cell lung cancer.p-Akt、p-mTOR 和 p-eIF4E 蛋白的过表达与非小细胞肺癌的转移和不良预后相关。
PLoS One. 2020 Feb 5;15(2):e0227768. doi: 10.1371/journal.pone.0227768. eCollection 2020.
7
Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer.新型亮氨酰 - tRNA合成酶抑制剂BC - LI - 0186对非小细胞肺癌的治疗作用
Ther Adv Med Oncol. 2019 May 19;11:1758835919846798. doi: 10.1177/1758835919846798. eCollection 2019.
8
Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?免疫组织化学在肺癌患者治疗预测生物标志物中能占据一席之地吗?
Cancers (Basel). 2018 Mar 13;10(3):70. doi: 10.3390/cancers10030070.
9
Upregulation of Neural Precursor Cell Expressed Developmentally Downregulated 4-1 is Associated with Poor Prognosis and Chemoresistance in Lung Adenocarcinoma.神经前体细胞表达发育下调蛋白 4-1 的上调与肺腺癌不良预后和化疗耐药相关。
Chin Med J (Engl). 2018 Jan 5;131(1):16-24. doi: 10.4103/0366-6999.221262.
10
Loss of phosphatase and tensin homolog expression correlates with clinicopathological features of non-small cell lung cancer patients and its impact on survival: A systematic review and meta-analysis.抑瘤素 M 同源物表达缺失与非小细胞肺癌患者临床病理特征及其对生存的影响的相关性:系统评价和荟萃分析。
Thorac Cancer. 2017 May;8(3):203-213. doi: 10.1111/1759-7714.12425. Epub 2017 Mar 6.